WHAT'S NEXT IN AI-ENABLED,
PRECISION CARDIAC CARE
Thank you for connecting with us at ACC.24
This year's ACC annual scientific session and expo was full of incredible energy and scientific discoveries. We were excited to see increased enthusiasm for the diagnostic benefits of using CCTA with AI analysis for earlier disease detection.
If you missed us at the conference, request your virtual demo of the Cleerly software platform to see firsthand how our technology can aid your workflow. We aim to remove the complexity of measuring atherosclerosis, stenosis, and ischemia. Our analysis can identify all three measure of cardiovascular health, and provide you with an actionable report to inform your treatment plan.
Below, see some highlights from the conference floor. We look forward to seeing you in 2025!
Cleerly's ACC Events
Demonstrations daily // Saturday through Monday at Booth 2131
Poster presentations in Hall B4-5 and Moderated Poster Theaters 05, 07, and 08
Saturday, April 6
9:00AM - 4:45PM
Exhibit Hall open // Cleerly Booth 2131
9:45AM - 10:30AM
Sarah Bär
Sarah Bär
Prognostic Value of a Novel Artificial Intelligence-Guided CCTA-Derived Ischemia Algorithm Among Patients Undergoing Selective Hybrid CCTA/PET Perfusion Imaging for Suspected Coronary Artery Disease
9:45AM - 10:30AM
Leslie Cho
Leslie Cho
Characteristics and Outcomes for Statin-Intolerant Women Receiving Bempedoic Acid in the CLEAR Outcomes Trial
10:15AM - 10:25AM
Shant Malkasian
Shant Malkasian
Automated Detection of Adverse Low-Density Non-calcified Plaque Morphology
1:45PM - 2:30PM
Fatima Rodriguez
Fatima Rodriguez
Characteristics and Outcomes for Statin-Intolerant Hispanic/Latinx Patients Receiving Bempedoic Acid: Results From a CLEAR Outcomes Pre-specified Sub-analysis
3:00PM - 4:00PM
Meet Cleerly Leadership and Partners
Sunday, April 7
9:00AM - 4:45PM
Exhibit Hall open // Cleerly Booth 2131
11:15AM - 12:00PM
Nick Nurmohamed
Nick Nurmohamed
Coronary Artery Disease Risk Factors, Symptoms, Physician Visits and Preventive Medical Therapy Prior to First Myocardial Infarction Among 4,657,412 Us Patients: Need for Improved Identification and Preventive Treatment
11:30AM - 11:40AM
Michael Holinstat
Michael Holinstat
Sotagliflozin, a First-in-Class SGLT1/2 Inhibitor, Inhibits Clotting Potential in the Vessel via Inhibition of Platelet Activation, Integrin Activation, and Aggregation in Human Platelets
1:15PM - 2:00PM
Samuel CR R. Sherratt
Samuel CR R. Sherratt
Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Glucose Transport and Inflammatory Proteins in Endothelial Cells Following Angiotensin II Stimulation
1:15PM - 2:00PM
Harold E. BaysWelcome
Harold E. BaysWelcome
Bempedoic Acid and Cardiovascular Disease Outcomes in Patients With Obesity: A CLEAR Outcomes Subset Analysis
2:15PM - 3:00PM
Muhammad Faraz Anwaar
Muhammad Faraz Anwaar
Relationship Between Differential Quantitative Coronary Plaque As Assessed on CCTA Across Various Measures of Obesity: Miami Heart Study at Baptist Health South Florida
3:15PM - 4:00PM
Juan Lopez
Juan Lopez
Return on Investment for a Novel Prevention Artificial Intelligence Guided CCTA Program
Monday, April 8
9:00AM - 2:00PM
Exhibit Hall open // Cleerly Booth 2131
8:40AM - 8:50AM
Sarah Bär
Sarah Bär
Artificial Intelligence-Guided Automated Non-calcified Plaque Burden Quantification on Coronary Computed Tomography Angiography Predicts the Long-term Risk for Myocardial Infarction Among Patients With Suspected Coronary Artery Disease
9:45AM - 10:30AM
Anoop Titus
Anoop Titus
Association of Cardiovascular Risk Factors to Quantitative Coronary Plaque Characteristics: Miami Heart Study at Baptist Health South Florida
9:45AM - 10:30AM
Muhammad Faraz Anwaar
Muhammad Faraz Anwaar
Variation of Coronary Atherosclerosis Across Spectrum of Increasing Lp(a) Using Quantitative CCTA Plaque Analysis: Miami Heart Study at Baptist Health South Florida
12:15PM - 12:25PM
Rahul Aggarwal
Rahul Aggarwal
Sotagliflozin Reduces Stroke Outcomes in Patients With Diabetes and Chronic Kidney Disease
Cleerly’s products and services may be covered by or for use under one or more patents.
See here for additional information.